ArticlePDF Available

Neurological Activity of Lion’s Mane ( Hericium erinaceus )

  • Health, Education & Research in Botanical Medicine

Abstract and Figures

Hericium erinaceus, most commonly known as lion’s mane, is an edible fungus, with a long history of use in Traditional Chinese Medicine. The mushroom is abundant in bioactive compounds including β-glucan polysaccharides; hericenones and erinacine terpenoids; isoindolinones; sterols; and myconutrients, which potentially have neuroprotective and neuroregenerative properties. Because of its anti-inflammatory properties and promotion of nerve growth factor gene expression and neurite (axon or dendrite) outgrowth, H. erinaceus mycelium shows great promise for the treatment of Alzheimer’s and Parkinson’s diseases. The fungus was well tolerated in two clinical studies, with few adverse events reported.
Content may be subject to copyright.
Journal of Restorative Medicine 2017; 6: page 19
Neurological Activity of Lion’s Mane (Hericium erinaceus)
Kevin Spelman, PhD, MCPPa
Elizabeth Sutherland, NDb
Aravind Bagade, MDc
©2017, Kevin Spelman, PhD, MCPP
Journal Compilation ©2017, AARM
DOI 10.14200/jrm.2017.6.0108
Hericium erinaceus, most commonly known as lion’s mane, is an edible fungus, with
a long history of use in Traditional Chinese Medicine. The mushroom is abundant in
bioactive compounds including β-glucan polysaccharides; hericenones and erinacine
terpenoids; isoindolinones; sterols; and myconutrients, which potentially have
neuroprotective and neuroregenerative properties. Because of its anti-inflammatory
properties and promotion of nerve growth factor gene expression and neurite
(axon or dendrite) outgrowth, H. erinaceus mycelium shows great promise for the
treatment of Alzheimer’s and Parkinson’s diseases. The fungus was well tolerated in
two clinical studies, with few adverse events reported.
Keywords: Lion’s mane; Neuroregeneration; Neurodegeneration; Neuroprotection;
Neurotropins; Neurotrophic; Alzheimer’s disease; Parkinson’s disease; Multiple
Sclerosis; Nerve growth factor
aCorresponding author: Health, Education & Research, POB 599, Ashland, OR 97520, USA,
Tel.: +1-541-708-3002; E-mail:
bAdjunct faculty National University of Natural Medicine, Portland, OR, USA
cExecutive Secretary and Researcher, Ayurveda Interdisciplinary Research Minds Association, Mysore, India
Journal of Restorative Medicine 2017; 6: page 20
Lion’s Mane Neurological Activity
Ancient, traditional, and modern cultures around
the world have known about the nutritive and
medicinal properties of mushrooms for centu-
ries. As early as 450 BCE, the Greek physician
Hippocrates identified mushrooms as potent
anti-inflammatory agents, useful for cauterizing
wounds. In the East, reverence for fungi is evident
in the Chinese description of ling zhi (Ganoderma
lucidum), as the “spirit plant,” believed to provide
longevity and spiritual potency.
Modern medicine has been slower to catch on to
the immense potential of fungi. Despite Fleming’s
1929 discovery of penicillin,1 and the subsequent
implementation of the fungi-chemical as a block-
buster pharmaceutical in the 1940s,2 it is only
in the last few decades that medical science has
looked beyond the antimicrobial and cholesterol-
lowering properties of fungi for other potential
Clinicians now have greater access to myce-
lium extracts, which are used clinically for their
cytotoxic, antineoplastic, cardiovascular, anti-
inflammatory, and immune-modulating activities.3–5
Functional studies and chemical assays also support
their potential to act as analgesic, antibacterial,
antioxidant, and neuroprotective agents. A number
of mushrooms, including Sarcodon scabrosus,
Ganoderma lucidum, Grifola frondosa, and
Hericium erinaceus are reported to have activi-
ties related to nerve and brain health.6 Hericium
erinaceus, a member of the Herinaceae family, is a
culinary and medicinal mushroom. Both the myce-
lium and fruiting bodies of H. erinaceus have been
shown to have therapeutic potential for brain and
nerve health.7 The unique neurological activities of
this fungus are the subject of this review.
Hericium erinaceus (lion’s mane, yamabushi-
take, or bearded tooth carpophore) grows on old
or dead broadleaf trees, and is used as both food
and medicine in parts of Asia. The fruiting body
is called hóu tóu gū (“monkey head mushroom”)
in Chinese8 and yamabushitake (“mountain monk
mushroom”) in Japanese. In Chinese and Japanese
medical systems, it has traditionally been used to
fortify the spleen, nourish the gut, and also as an
anticancer drug.9 Lion’s mane is said to be nutri-
tive to the five internal organs (liver, lung, spleen,
heart, and kidney), and promotes good digestion,
general vigor, and strength. It is also recommended
for gastric and duodenal ulcers, as well as chronic
gastritis (in prepared tablet form).10 The mushroom
is also known for its effects on the central nervous
system, and is used for insomnia, vacuity (weak-
ness), and hypodynamia, which are characteristic
symptoms of Qi deficiency in Traditional Chinese
medicine (TCM).
The bioactive metabolites of H. erinaceus can be
classified into high molecular weight compounds,
such as polysaccharides, and low molecular
weight compounds, such as polyketides and
Fungal polysaccharides are found mainly in cell
walls, and are present in large quantities in both
fruiting bodies and cultured mycelium. Hericium
erinaceus fruiting bodies (HEFB) contain immu-
noactive β-glucan polysaccharides, as well as
α-glucans and glucan-protein complexes.12 A total
of more than 35 H. erinaceus polysaccharides
(HEP) have been extracted to date from cultured,
wild-growing, or fermentative mycelia and fresh/
dried fruiting bodies. Of these β-glucans represent
the main polysaccharides. HEP are composed of
xylose (7.8%), ribose (2.7%), glucose (68.4%),
arabinose (11.3%), galactose (2.5%), and mannose
(5.2%).4 Four different polysaccharides isolated
from the H. erinaceus sporocarp show antitumor
activity: xylans, glucoxylans, heteroxyloglucans,
and galactoxyloglucans.5 Chemical analysis shows
that the total content of HEP found in fruiting bod-
ies is higher than that in mycelium. Table 1 lists the
Journal of Restorative Medicine 2017; 6: page 21
Lion’s Mane Neurological Activity
polysaccharides along with their source and chemi-
cal composition.
Studies of the polysaccharides found in
H. erinaceus reveal a number of activities. For
example, extracellular and intracellular polysac-
charides showed a protective effect on oxidative
hepatotoxicity in mice.11 Neuroprotective effects of
HEPs were observed in an in vitro model of cells
that were toxic from amyloid β plaque formation.
In this model, HEPs decreased the production of
reactive oxygen species from 80% to 58% in a dose-
dependent manner, and increased the efficacy of free
radical scavenging. HEPs also promoted cell viabil-
ity and protected cells against apoptosis induced
by amyloid β plaque formation.13 HEPs decreased
blood lactic acid, serum urea nitrogen, tissue glyco-
gen, and malondialdehyde, further supporting the
beneficial role of HEPs on oxidative stress.14
Terpenoids are a class of naturally occurring
hydrocarbons that consist of terpenes attached to an
oxygen containing group. Terpenoids make up over
60% of products in the natural world.15,16
A variety of diterpenes and sesterpenes are found
in the fruiting body and fermenting mycelium of
H. erinaceus.17 Of particular pharmacological inter-
est are two classes of terpenoid compounds thus far
known to occur only in Hericium spp.: hericenones
(C–H), a group of aromatic compounds isolated
from the fruiting body; and erinacines (A–I), a
group of cyathane-type diterpenoids found in the
mycelium.18 Both groups of substances easily cross
the blood-brain barrier, and have been found to have
neurotrophic and in some cases neuroprotective
effects.19 Erinacines (A–I) have demonstrated induc-
tion of nerve growth factor (NGF) synthesis.20 Table
2 lists the terpenoids, sesterpenes, and diterpenoids
along with their source and chemical composition.
Ten erinarols, described as erinarol A–J, five
ergostane-type sterol fatty acid esters, and ten
ergostane-type sterols have been identified in the
fruiting body of H. erinaceus.21 Sterols, such as
Table 1: Polysaccharides: source and composition.
Polysaccharides No. Isolated from Composition
(FI0-a, FI0-a-α, FI0-a-β, FI0-b,
FII-1, FIII-2b)
6Fresh fruiting bodies of H.
Xylans, glucoxylans,
heteroxyloglucans, and
AF2S-2, BF2S-2 2 Fresh fruiting bodies Backbone of β-(l6)-linked
D-glucopyranosyl residues,
and had β-(13) and
β-(l6) glucosidic linkages
Heteropolysaccharides (HEPA1,
3 Mycelium Glucose
Water extractable polysaccharides
(HPA and HPB)
2 Aqueous extract Glucose and galactose
Water soluble polysaccharide
1H. caput-medusae Glucose and galactose
Neutral heteropolysaccharides
(HEP-1 and HEP-4)
2 Fruiting bodies Glucose
Glucans HEP-3 (β-glucan) and
HEP-5 (α glucan)
2 Fruiting bodies Glucose
Acidic polysaccharide (HEP-2) 1 Fruiting bodies Uronic acid
Heteropolysaccharide (HPB-3) 1 The maturating-stage IV,
V, and VI fruiting body
I-fucose, d-galactose and
Homopolysaccharides, a neutral
glucan (HPP)
1 Fermentative mycelia Glucose
Journal of Restorative Medicine 2017; 6: page 22
Lion’s Mane Neurological Activity
ergosterol confer antioxidative properties.21,22
Hericium erinaceus has been found to be the most
potent in vitro inhibitor of both low-density lipo-
protein (LDL) oxidation and HMG Co-A reductase
activity, suggesting therapeutic potential for the
prevention of oxidative stress-mediated vascular
Hericenones and erinacines isolated from
H. erinaceus have demonstrated neuroprotective
properties.24 Hericium erinaceus mycelia (HEM),
and its isolated diterpenoid derivative, erinacine A,
reduced infarction by 22% at 50 mg/kg and 44% at
300 mg/kg in an animal model of global ischemic
stroke. This effect was thought to be partially medi-
ated by its ability to reduce cytokine levels.25
A purified polysaccharide from the liquid culture
broth of HEM was also found to possess neuro-
protective activity in an in vitro model through a
dramatic delay of apoptosis, which was 20%–50%
greater than that seen in the control sample. The
same study showed HEM to be more effective than
control, NGF, or brain-derived neurotrophic fac-
tor (BDNF) alone in enhancing the growth of rat
adrenal nerve cells and neurite (axon or dendrite)
extension.26 However, in a model of NG108-15
neuroblastoma cells subjected to H2O2 oxidative
stress in pre-treatment and co-treatment, the aque-
ous extract of H. erinaceus (as opposed to a purified
polysaccharide), failed to show a protective effect.27
Although it is challenging to draw clinically rele-
vant conclusions from in vitro studies, this suggests
that water extracts would not have a neuroprotec-
tive effect without one particular polysaccharide
being highly concentrated.
The addition of an ethanol extract of HEFB resulted
in NGF gene expression in human astrocytoma
cells, in a concentration-dependent manner. Neurite
outgrowth was also improved. The same investi-
gators also observed that mice fed 5% HEFB dry
powder for 7 days, showed an increase in the level
of NGF mRNA expression in the hippocampus.28
Another study showed that an aqueous extract of
HEFB increased secretion of extracellular NGF
and neurite outgrowth activity. These researchers
also observed a synergistic interaction between
H. erinaceus aqueous extract and exogenous
NGF on neurite outgrowth stimulation of neuro-
blastoma-glioma cells at physiologically relevant
concentrations (1 μg/mL HEFB extract +10 ng/mL
NGF).21 Myelin sheath formation in the presence
of H. erinaceus extract proceeded at a higher rate
and was completed by day 26, as compared to day
31 in controls. No toxic effects of the extracts were
observed in this model.30
In a behavior test on wild-type mice, oral
supplementation with H. erinaceus induced a
Table 2: Sesterpenes and diterpenoids: source and composition.
Terpenoids Isolated from Composition
Fresh fruiting bodies of H. erinaceus
Erinacerins C–L together with
(E)-5- (3,7- methylocta-2,6-dien-
Diterpenoids Fresh fruiting bodies of H. erinaceusErinacines A–I
Isoindolinones Fresh fruiting bodies of H. erinaceusErinaceolactams A–E, hericenone
A, hericenone J, N-De
phenylethylisohericerin, erinacerin A,
and hericerin
Journal of Restorative Medicine 2017; 6: page 23
Lion’s Mane Neurological Activity
statistically significant improvement in spatial
short-term and visual recognition memory.31 In a
double-blind placebo-controlled clinical trial of
50–80-year-old Japanese adults (n=30) diagnosed
with mild cognitive impairment, oral intake of
H. erinaceus 250 mg tablets (96% dry powder)
three times a day for 16 weeks was associ-
ated with marked improvement in the revised
Hasegawa Dementia Scale (HDS-R) as compared
to controls. Scores on the HDS-R decreased,
however, by 4 weeks after cessation of the
In a mouse model of Alzheimer’s disease, oral
administration of HEFB increased expression of
NGF mRNA in the hippocampus, and prevented
impairments of spatial, short-term, and visual
recognition memory induced by amyloid β plaque
that were observed in non-treated mice.28 In another
study using an Alzheimer’s model of mice that
develop amyloid plaque deposits by 6 months of
age, a 30-day oral administration of HEM resulted
in fewer plaque deposits in microglia and astro-
cytes in the cerebral cortex and hippocampus.32
In an aluminum chloride induced animal model
of Alzheimer’s disease, HEM increased serum
and hypothalamic concentrations of acetylcholine
and choline acetyltransferase in a dose-dependent
manner.29 Figure 1 illustrates the apparent mecha-
nisms of action for the effects that H. erinaceus
may have in Alzheimer’s disease.
Oral administration of low-dose HEM (10.76
or 21.52 mg/day) used in an animal model of
Parkinson’s disease led to significant improve-
ment in oxidative stress and dopaminergic lesions
in the striatum and substantia nigra after 25
An aqueous extract of HEFB that was admin-
istered to animals at a dose of 10 mL/kg for
14 days following crush injury improved nerve
regeneration and increased the rate of motor
functional recovery. The animals treated with
HEFB recovered 4–7 days earlier than animals in
the control group, as assessed by walking track
analysis. Normal toe spreading, a measure of
reinnervation, was achieved 5–10 days earlier
in the aqueous extract group than in the control
group. Based on functional evaluation and the
morphological examination of regenerated nerves,
ipsilateral dorsal root ganglia, and target extensor
digitorum longus muscles, researchers concluded
that HEFB aqueous extract promoted peripheral
Figure 1: Mechanism of action of Hericium erinaceus in Alzheimer’s disease.
Journal of Restorative Medicine 2017; 6: page 24
Lion’s Mane Neurological Activity
nerve regeneration with significant functional
As previously described under Cognitive
Function, a double-blind placebo-controlled study
of 50–80-year-old Japanese men and women
(n=30) diagnosed with mild cognitive impair-
ment showed marked improvement in cognitive
function, as measured by the revised Hasegawa
Dementia Scale (HDS-R), when compared to
controls, following oral intake of H. erinaceus
250 mg tablets (96% dry powder) three times
a day for 16 weeks. Scores on the HDS-R
decreased, however, by 4 weeks after cessation of
the intervention.28
In another clinical trial, administration of HEFB
at 2.0 g/day (in cookies) over 4 weeks showed a
reduction in some symptoms of anxiety and depres-
sion in menopausal women (n=30). The Indefinite
Complaints Index categories for Palpitation
and Incentive showed a statistically significant
improvement in women taking HEFB compared to
those taking placebo. The categories of Irritating,
Anxious, and Concentration indicated a trend in the
direction of improvement with HEFB as compared
to placebo.29 Table 3 summarizes the two clinical
trials reported on in this paper.
The recommended dose of H. erinaceus dried
fruiting body for increasing NGF production is
3–5 g per day.34 Hericium erinaceus dosed at
250 mg tablets (96% dry powder) three times a
day for 16 weeks was associated with signifi-
cant improvement on a dementia rating scale in
subjects with mild cognitive impairment.28 The
dose utilized in the study of menopausal women
that showed reduction in symptoms of depression
and anxiety was 2.0 g/day of HEFB (in cookies)
for 4 weeks.29
In an in vitro model, HEFB aqueous extract
demonstrated a remarkable lack of cytotoxicity.31
Toxicology studies of H. erinaceus in rats suggest
that mycelia enriched with 5 mg/g erinacine A at
doses of up to 5 g/kg bodyweight/day are safe. No
toxicity was found in the two clinical trials reported
on here.28,29
No adverse clinical or biochemical events were
reported in the clinical trial of subjects with
mild cognitive impairment.28 In the study of
Table 3: Outcomes of clinical trials of H. erinaceus.
Trial Parameter
Results Adverse events Dose Citation
Mild cognitive
Hasegawa Dementia
Scale (HDS-R)
in cognitive
function scale
None 250 mg tid×16 weeks Mori et al., 200928
Anxiety and
for Epidemiologic
Studies Depression
Scale (CES-D)
and Indefinite
Complaints Index
improvement in
some anxiety and
depression scores
None 2 g/day×4 weeks Nagano et al., 201029
Journal of Restorative Medicine 2017; 6: page 25
Lion’s Mane Neurological Activity
1. Hobbs C. Medicinal Mushrooms, 3rd edn. Santa Cruz:
Botanica Press; 1995.
2. Zhou J, Xie G, Yan X. Encyclopedia of Molecular
Structures, Pharmacological Activities, Natural Sources
and Applications Traditional Chinese Medicines Vol. 5:
Isolated Compounds TZ. Berlin Heidelberg: Springer-
Verlag; 2011.
3. Kwagishi H, Shimada A, Shirai R, et al. Erinacines A, B
and C strong stimulators of nerve growth factor (NGF)-
synthesis from the mycelia of Hericium erinaceum.
Tetrahedron Lett. 1994;35:1569–72.
4. Shen JW, Yu HY, Ruan Y, et al. Hericenones and
erinacines: stimulators of nerve growth factor (NGF)
biosynthesis in Hericium erinaceus. Mycol Int J Fungal
Biol. 210;1:92–8.
5. Mizuno T, Wasa T, Ito H, et al. Antitumor-active poly-
saccharides isolated from the fruiting body of Hericium
erinaceum, an edible and medicinal mushroom called
Yamabushitake or Houtou. Biosci Biotechnol Biochem.
6. He X, Wang X, Fang J, et al. Structures, biological
activities, and industrial applications of the polysaccha-
rides from Hericium erinaceus (Lion’s Mane) mushroom:
a review. Int J Biol Macromol. 2017;97:228–37.
7. Cheng JH, Tsai CL, Lien YY, et al. High molecular
weight of polysaccharides from Hericium erinaceus
against amyloid beta-induced neurotoxicity. BMC
Complement Altern Med. 2016;16:170.
8. Cui F, Gao X, Zhang J, et al. Protective effects of
extracellular and intracellular polysaccharides on hepa-
totoxicity by Hericium erinaceus SG-02. Curr Microbiol.
9. Liu J, Du C, Wang Y, Yu Z. Anti-fatigue activities of
polysaccharides extracted from Hericium erinaceus. Exp
Ther Med. 2015;9(2):483–7.
10. Thongbai B, Rapior S, Hyde KD, et al. Hericium
erinaceus, an amazing medicinal mushroom. Mycol
Progress. 2015;14:91.
11. Wang K, Bao L, Qi Q, et al. Erinacerins C-L, isoindolin-
1-ones with alpha-glucosidase inhibitory activity from
cultures of the medicinal mushroom Hericium erinaceus.
J Nat Prod. 2015;78(1);146–54.
12. Moldavan MG, Gryganski AP, Kolotushkina OV,
et al. Neurotropic and trophic action of lion’s
mane mushroom Hericium erinaceus (Bull.: Fr.)
Pers. (Aphyllophoromycetideae) extracts on
nerve cells in vitro. Int J Med Mushrooms.
menopausal women, one subject reported epi-
menorrhea (18 days menorrhea/month). However,
whether or not supplementation with H. eri-
naceus was the cause of the epimenorrhea is
Allergies and sensitivities to mushrooms are not
unusual. One case report describes a 63-year-old
male who suffered acute respiratory failure and
lymphocytosis in his lungs. The report suggests
he had used an extract of dry H. erinaceus (with
no further description given) daily for 4 months
in commonly available doses, and the connection
between the two was considered to be probable. In
another case report, a 53-year-old male exposed to
HEFB occupationally, developed chronic dermatitis
on his hands, with painful fissures within 1 month
of exposure. The dermatitis spread to his forearms,
face, and legs, at which point he ceased exposure
to the HEFB and his symptoms resolved. His
patch tests were negative for the European stan-
dard series, and positive for HEFB. Sensitization
was confirmed by a highly positive repeated open
application test (ROAT) with an aqueous emulsion
of HEFB. Interestingly, patch and prick tests were
negative for other culinary mushrooms suggesting a
lack of cross-sensitivity.
To the best of this author’s knowledge, no toxicity
was established for H. erinaceus in the experimen-
tal, animal, or two clinical trials reported here. The
adverse event (epimenorrhea) reported in one of the
clinical trials could not be conclusively attributed to
the intervention. The substantial historical record for
the traditional use of lion’s mane for chronic ailments,
together with the results of studies so far, suggest
H. erinaceus is safe and has important potential as a
neuroprotective and neurotrophic therapeutic agent
in neurological conditions.35 Its rich myconutrient
composition suggest that using the whole fungus may
be most advantageous clinically. More clinical studies
are needed to corroborate these conclusions.
The authors declare they have no competing interests.
Journal of Restorative Medicine 2017; 6: page 26
Lion’s Mane Neurological Activity
13. Li JL, Lu L, Dai CC, et al. A comparative study on ste-
rols of ethanol extract and water extract from Hericium
erinaceus. Zhongguo Zhong Yao Za Zhi. 2001;26:831−4.
14. Abdullah N, Ismail SM, Aminudin N, et al. Evaluation of
selected culinary-medicinal mushrooms for antioxidant
and ACE inhibitory activities. Evid Based Complement
Alternat Med. 2012 (2012), Article ID 464238, 12 pages.
15. Gershenzon J, Dudareva N. The function of terpene
natural products in the natural world. Nat Chem Biol.
16. Chappell J. The genetics and molecular genetics of
terpene and sterol origami. Curr Opin Plant Biol.
17. Guillamón E, García-Lafuente A, Lozano M, et al.
Edible mushrooms: role in the prevention of cardiovas-
cular diseases. Fitoterapia. 2010;81(7):715–23.
18. Rahman MA, Abdullah N, Aminudin N. Inhibitory
effect on in vitro LDL oxidation and HMG Co-A
reductase activity of the liquid-liquid partitioned frac-
tions of Hericium erinaceus (Bull.) Persoon (lion’s
mane mushroom). BioMed Res Int. 2014;2014:828149.
19. Lee KF, Chen JH, Teng CC, et al. Protective effects of
Hericium erinaceus mycelium and its isolated erinacine
A against ischemia-injury-induced neuronal cell death
via the inhibition of iNOS/p38 MAPK and nitrotyrosine.
Int J Mol Sci. 2014;15(9):15073–89.
20. Yaoita Y, Kakuda R, Machida K, et al. Ceramide con-
stituents from five mushrooms. Chem Pharmaceut Bull.
21. Mori K, Obara Y, Hirota M, et al. Nerve growth
factor-inducing activity of Hericium erinaceus in
1321N1 human astrocytoma cells. Biol Pharm Bull.
22. Mori K, Obara Y, Moriya T, et al. Effects of Hericium
erinaceus on amyloid beta(25–35) peptide-induced
learning and memory deficits in mice. Biomed Res.
23. Tzeng TT, Chen CC, Lee LY, et al. Erinacine A-enriched
Hericium erinaceus mycelium ameliorates Alzheimer’s
disease-related pathologies in APPswe/PS1dE9 trans-
genic mice. J Biomed Sci. 2016;23:49.
24. Trovato A, Siracusa R, Di Paola R, et al. Redox
modulation of cellular stress response and lipoxin A4
expression by Hericium erinaceus in rat brain: relevance
to Alzheimer’s disease pathogenesis. Immun Ageing.
25. Zhang J, An S, Hu W, et al. The neuroprotective
properties of Hericium erinaceus in glutamate-damaged
differentiated PC12 cells and an Alzheimer’s disease
mouse model. Int J Mol Sci. 2016;17(11);1810.
26. Kuo HC, Lu CC, Shen CH, et al. Hericium eri-
naceus mycelium and its isolated erinacine A protection
from MPTP-induced neurotoxicity through the ER
stress, triggering an apoptosis cascade. J Translat Med.
27. Wong KH, Naidu M, David RP, et al. Neuroregenerative
potential of lion’s mane mushroom, Hericium erinaceus
(Bull.: Fr.) Pers. (higher Basidiomycetes), in the treat-
ment of peripheral nerve injury (review). Int J Med
Mushrooms. 2012;14(5):427–46.
28. Mori K, Inatomi S, Ouchi K, et al. Improving
effects of the mushroom Yamabushitake (Hericium
erinaceus) on mild cognitive impairment: a double-
blind placebo-controlled clinical trial. Phytother Res.
29. Nagano M, Shimizu K, Kondo R, et al. Reduction of
depression and anxiety by 4 weeks Hericium erinaceus
intake. Biomed Res. 2010;31:231–7.
30. Operational guidance: Information needed to support
clinical trials of herbal products.
31. Lai PL, Naidu M, Sabaratnam V, et al. Neurotrophic
properties of the Lion’s mane medicinal mushroom,
Hericium erinaceus (Higher Basidiomycetes) from
Malaysia. Int J Med Mushrooms. 2013;15(6);539–54.
32. Chinese pharmacopoeia. Beijing: Chinese Medicine
Science and Technology Publishing House; 2010.
33. Wong KH, Naidu M, David P, et al. Peripheral
nerve regeneration following crush injury to rat
peroneal nerve by aqueous extract of medicinal
mushroom Hericium erinaceus (Bull.: Fr) Pers.
(Aphyllophoromycetideae). Evid Based Complement
Alternat Med. 2011;2011:580752.
34. Tanaka A, Matsuda H. Expression of nerve growth factor
in itchy skins of atopic NC/NgaTnd mice. J Vet Med Sci.
35. Nakatsugawa M, Takahashi H, Takezawa C, et al.
Hericium erinaceum (yamabushitake) extract-induced
acute respiratory distress syndrome monitored by serum
surfactant proteins. Intern Med. 2003;42:1219–22.
... The medicinal properties of H. erinaceus include antioxidant, antimicrobial and anticancer effects [7]. Recently, interest has been placed on the potential neuroprotective and neuroregenerative properties of H. erinaceus [8,9]. These are likely underpinned by the numerous bioactive components identified within the mycelia and fruiting bodies of H. erinaceus, including polysaccharides, phenolic acids and terpenoids, specifically hericenones and erinacines [6,9]. ...
... Recently, interest has been placed on the potential neuroprotective and neuroregenerative properties of H. erinaceus [8,9]. These are likely underpinned by the numerous bioactive components identified within the mycelia and fruiting bodies of H. erinaceus, including polysaccharides, phenolic acids and terpenoids, specifically hericenones and erinacines [6,9]. Interestingly, both hericenones and erinacines can easily cross the blood-brain barrier [10]; promote nerve growth factor synthesis and secretion [11,12]; and, in animal models, have been shown to exert anti-neuroinflammatory and neuroprotective properties [4,[13][14][15] and promising cognition-enhancing effects [16,17]. ...
Full-text available
Background: Given the bioactive properties and limited work to date, Hericium erinaceus (Lion’s mane) shows promise in improving cognitive function and mood. However, much of the human research has concentrated on chronic supplementation in cognitively compromised cohorts. Objective: The current pilot study investigated the acute and chronic (28-day) cognitive and mood-enhancing effects of Hericium erinaceus in a healthy, young adult cohort. Design: This randomized, double-blind, placebo-controlled, parallel-groups design investigated the acute (60 min post dose) and chronic (28-day intervention) effects of 1.8 g Hericium erinaceus in 41 healthy adults aged 18–45 years. Results: Analysis revealed that following a single dose of Hericium erinaceus, participants performed quicker on the Stroop task (p = 0.005) at 60 min post dose. A trend towards reduced subjective stress was observed following 28-day supplementation (p = 0.051). Conclusions: The findings tentatively suggest that Hericium erinaceus may improve speed of performance and reduce subjective stress in healthy, young adults. However, null and limited negative findings were also observed. Given the small sample size, these findings should be interpreted with caution. Further investigation in larger sample sizes is crucial, however the findings of this trial offer a promising avenue of interest.
... H. erinaceus, also known as lion's mane mushroom, is an edible mushroom belonging to the tooth fungus group [119,120]. H. erinaceus contains hericenones and erinacines, compounds shown to have potential neuroprotective effects [121,122]. Hericenones stimulate the production of nerve growth factors, such as brain-derived neurotrophic factor (BDNF), which is crucial for the growth and maintenance of neurons [123]. By promoting the growth and protection of neurons, hericenones may help to support brain health and potentially slow down the progression of neurodegenerative diseases such as Alzheimer's [124]. ...
Full-text available
Mushrooms are new potential sources of valuable medicines, long neglected because of difficulties experienced in their cultivation. There is a large variety of medicinal mushrooms which possess significant therapeutic properties and are used as medications for various diseases because they contain several novel highly bioactive components. Medicinal mushrooms can be identified based on their morphology, size, mass, and the color of the stalk, cap and spore, and attachment to the stalk. Medicinal mushrooms possess a variety of important biological activities and are used as antioxidants, hepatoprotectors, anticancer, antidiabetic, anti-inflammatory, antiaging, antiviral, antiparasitic, and antimicrobial agents, among others. This review provides a basic overview of the chemical scaffolds present in mushrooms and their therapeutic implications in the human body.
... According to reports, medicinal mushrooms (MMs) have a wide range of pharmacological effects, including prebiotic, antibacterial, anti-inflammatory, immunomodulatory, antidiabetic, cytotoxic, and antioxidant qualities. They also have hepatoprotective, anticancer, antiallergic, and antihyperlipidemic capabilities [84] [105] [288] [135] [314]. Many bioactive metabolites found in the mycelium, but especially in the fruiting body, are responsible for these activities. ...
Full-text available
The purpose of this paper is to review and evaluate published literature on mushroom cultivation and production and the range of benefits and therapeutic potential. A systematic method was used to gather the relevant literature. A total of twenty-six research papers published between the years 1970 to 2022 were selected and utilized in this review. Tables were used to present the results and relevant figures were used to place emphasis on contents discussed. In this paper five (5) benefits and nine (9) therapeutic potentials were evaluated and reported on. Some medicinal mushrooms and their uses and bioactive compounds were also discussed in this paper. Additionally, mushroom cultivation and production was addressed as well as challenges associated with mushroom farming and an assessment of their nutritional content compared to other food consumed by humans. The published papers established that mushrooms have been massed produced and harvested for a long time and their benefits are well documented in countries outside the neotropics. More studies to investigate the uses of mushrooms should be done, in Guyana and other neotropical countries as there is a paucity of information in this region with high natural biodiversity.
... erinaceus* extract (250 mg, three times a day), showed a significant improvement in cognitive function compared to the control group. [211] The bioactive substances in mushrooms also have great potential in cancer treatment. Panda and Luyten [212] summarized the relevant data of medicinal mushrooms in clinical research, and the results showed that the treatment of cancer accounted for 16% in clinical research, which is the largest proportion of all diseases treated. ...
Mushrooms have been an acclaimed food for their unique flavor and medicinal properties since ancient times. Modern research shows that mushrooms are rich in various nutrients and biologically active substances. In recent years, researchers have become increasingly interested in mushrooms because they contain important secondary metabolites, such as phenolic compounds with significant bioactive properties. This review introduces the nutritional components and secondary metabolites in mushrooms, focusing on the bioactive functions and potential applications of mushroom polyphenols. Finally, the current challenges and future research trends of mushroom polyphenols are briefly discussed. In the aspect of nutritional value, mushrooms are high in protein and insoluble fiber, while low in fat and sodium, making them a low-energy, healthy food. Mushrooms contain a large amount of beneficial bioactive substances for health, including phenolic compounds, as well as tocopherols, terpenoids, and phytosterols. Mushroom polyphenols have antioxidant, anti-inflammatory, anti-cancer, anti-tyrosine, antihyperglycemic, and other biological activities beneficial to human health and medical applications, especially in the various degenerative disease and cancer treatments. However, based on the properties of phenolic compounds, research and development in commercial applications still face many issues that need to be addressed by researchers.
Medicinal plants exhibit a broad range of potential for nutraceuticals, presenting a diverse assortment of bioactive compounds that confer notable health advantages beyond fundamental nourishment. These chemical compounds, which encompass polyphenols, flavonoids, alkaloids, terpenoids, and essential oils, demonstrate a wide range of biological activities, including antioxidant, anti-inflammatory, antimicrobial, and anticancer effects. The potential applications of nutraceuticals derived from medicinal plants exhibit promising prospects, encompassing disease prevention and management as well as the promotion of overall well-being. Additionally, the accessibility and affordability of these natural sources, coupled with their potential synergistic effects, render them appealing alternatives to traditional pharmaceuticals. However, it is imperative to address challenges pertaining to standardization, quality control, and regulatory frameworks in order to fully harness the potential of medicinal plants as valuable sources of nutraceuticals. The primary objective of this chapter is to investigate the extent of nutraceuticals obtained from medicinal plants and their importance in enhancing human welfare, while also acknowledging the obstacles and future prospects in the field of nutraceutical research.
Medicinal mushrooms have been used for thousands of years as natural medicine. The bioactive constituents found within the mushroom products are responsible for therapeutic effects such as anti-inflammatory, anticancer, antioxidant, and antiviral activities. Since SARS-CoV-2 (COVID-19) became prevalent in December 2019, new research has emerged to explore potential treatment options since there was no FDA-approved product for treatment or prevention. Of the many mushrooms available, those with perhaps the highest medicinal values were discovered to include Reishi, Lion’s mane, Cordyceps, Shiitake, and Turkey tail. Each contains one or more bioactive compounds with evidence of therapeutic activity that can aid disease treatment or prevention. Few mushrooms have been studied regarding their activity in treating and preventing COVID-19. The specific medicinal mushrooms impacting COVID-19 infection discussed in this chapter include the following: Agaricus blazei Murill, Ganoderma lucidum, Hercium erinaceus, Grifola frondose, Inonotus obliquus, Lentinus edodes, Cordyceps militaris, Antrodia cinnamomea, Antrodia salmonea, Pseudoplectania nigrella, Russula paludosa, Clitocybe sinopica, Polyozellus multiplex, Psilocybin, Coriolus versicolor, and Sinomenium acutum.KeywordsBioactive constituentsCOVID-19Medicinal mushroomsSARS-CoV-2
Amyloid precursor protein profusion in Trisomy 21, also called Down Syndrome (DS), is rooted in the genetic determination of Alzheimer's disease (AD). With the recent development in patient care, the life expectancy of DS patients has gradually increased, leading to the high prospect of AD development, consequently leading to the development of plaques of amyloid proteins and neurofibrillary tangles made of tau by the fourth decade of the patient leading to dementia. The altered gene expression resulted in cellular dysfunction due to impairment of autophagy, mitochondrial and lysosomal dysfunction, and copy number variation controlled by the additional genes in Trisomy 21. The cognitive impairment and mechanistic insights underlying DS-AD conditions have been reviewed in this article. Some recent findings regarding biomarkers and therapeutics of DS-AD conditions were highlighted in this review.
Full-text available
Hericium erinaceus (hydne hérisson) est un basidiomycète lignicole à la forme étonnante, constitué de touffes d'aiguillons blancs tombant en cascade. Il est devenu rare mais est aisément cultivé et des productions très importantes se déroulent en Asie. Hericium erinaceus est utilisé depuis des centaines d'années dans les pratiques holistiques traditionnelles en Asie. Il synthétise de nombreux composés bioactifs de natures diverses, avec de multiples effets sur l'animal et l'homme. Les activités les plus remarquables et spécifiques sont liées au système nerveux. Il peut améliorer le développement et le fonctionnement des nerfs. Il peut également empêcher les nerfs d'être endommagés. Il pourrait ainsi contribuer à prévenir des affections telles que, la maladie d'Alzheimer ou la maladie de Parkinson l'anxiété, la perte de mémoire. Les métabolites actifs les plus importants sont les héricénones et érinacines, spécifiques à ce genre. Il a été, et reste, fort utilisé pour les problèmes gastro-intestinaux. Aucun médicament n'a encore été formulé à partir de ce champignon. Il est cependant disponible sous forme de poudre ou d'extrait comme régénérant, stimulateur de la mémoire, du bien-être. Il faut bien entendu suivre les règles de prudence.
Full-text available
Cervical cancer is one of the leading causes of death among women. Due to incomplete knowledge and hidden symptoms, it is not easily diagnosable. After the diagnosis of cervical cancer at an advanced stage, treatment such as chemotherapy and radiation therapy become too much costly along with having many side effects such as hair loss, loss of appetite, nausea, tiredness, etc. β-Glucan does a novel polysaccharide has many immunomodulatory properties. In our research, we have tested the efficacy of Agaricus bisporus derived β-Glucan particles (ADGPs) as an antimicrobial, antioxidant and anticancer agent against the cervical cancer HeLa cells. Prepared particles were quantified for carbohydrate content by anthrone test and further HPTLC analysis to confirm the polysaccharide nature and 1,3 glycosidic linkages of β-Glucan. ADGPs were found to have efficient antimicrobial activity against various fungal and bacterial tested strains. DPPH assay confirmed the antioxidant activity of ADGPs. Cell viability was assessed against the cervical cancer cell line by using the MTT and IC50 was found at 54μg/ml. Furthermore, β-Glucan was found to induce a significant amount of ROS, leading to the apoptosis of cells. The same was also assessed with the help of Propidium Iodide (PI) staining. With the help of JC-1 staining, β-Glucan was found to disrupt the Mitochondrial Membrane Potential (MMP), ultimately resulting in the cancer cell HeLa death. Based on our experimental findings, we found that ADGPs can be proven as an efficient therapy for cervical cancer treatment and work as an antimicrobial and antioxidant agent.
Full-text available
Hericium erinaceus, an edible and medicinal mushroom, displays various pharmacological activities in the prevention of dementia in conditions such as Parkinson’s and Alzheimer’s disease. The present study explored the neuroprotective effects of H. erinaceus mycelium polysaccharide-enriched aqueous extract (HE) on an l-glutamic acid (l-Glu)-induced differentiated PC12 (DPC12) cellular apoptosis model and an AlCl3 combined with d-galactose-induced Alzheimer’s disease mouse model. The data revealed that HE successfully induced PC12 cell differentiation. A 3 h HE incubation at doses of 50 and 100 µg/mL before 25 mM of l-Glu effectively reversed the reduction of cell viability and the enhancement of the nuclear apoptosis rate in DPC12 cells. Compared with l-Glu-damaged cells, in PC12 cells, HE suppressed intracellular reactive oxygen species accumulation, blocked Ca²⁺ overload and prevented mitochondrial membrane potential (MMP) depolarization. In the Alzheimer’s disease mouse model, HE administration enhanced the horizontal and vertical movements in the autonomic activity test, improved the endurance time in the rotarod test, and decreased the escape latency time in the water maze test. It also improved the central cholinergic system function in the Alzheimer’s mice, demonstrated by the fact that it dose-dependently enhanced the acetylcholine (Ach) and choline acetyltransferase (ChAT) concentrations in both the serum and the hypothalamus. Our findings provide experimental evidence that HE may provide neuroprotective candidates for treating or preventing neurodegenerative diseases.
Full-text available
Background: There has been a recent upsurge of interest in complementary medicine, especially dietary supplements and foods functional in delaying the onset of age-associated neurodegenerative diseases. Mushrooms have long been used in traditional medicine for thousands of years, being now increasingly recognized as antitumor, antioxidant, antiviral, antibacterial and hepatoprotective agent also capable to stimulate host immune responses. Results: Here we provide evidence of neuroprotective action of Hericium Herinaceus when administered orally to rat. Expression of Lipoxin A4 (LXA4) was measured in different brain regions after oral administration of a biomass Hericium preparation, given for 3 month. LXA4 up-regulation was associated with an increased content of redox sensitive proteins involved in cellular stress response, such as Hsp72, Heme oxygenase -1 and Thioredoxin. In the brain of rats receiving Hericium, maximum induction of LXA4 was observed in cortex, and hippocampus followed by substantia Nigra, striatum and cerebellum. Increasing evidence supports the notion that oxidative stress-driven neuroinflammation is a fundamental cause in neurodegenerative diseases. As prominent intracellular redox system involved in neuroprotection, the vitagene system is emerging as a neurohormetic potential target for novel cytoprotective interventions. Vitagenes encode for cytoprotective heat shock proteins 70, heme oxygenase-1, thioredoxin and Lipoxin A4. Emerging interest is now focussing on molecules capable of activating the vitagene system as novel therapeutic target to minimize deleterious consequences associated with free radical-induced cell damage, such as in neurodegeneration. LXA4 is an emerging endogenous eicosanoid able to promote resolution of inflammation, acting as an endogenous "braking signal" in the inflammatory process. In addition, Hsp system is emerging as key pathway for modulation to prevent neuronal dysfunction, caused by protein misfolding. Conclusions: Conceivably, activation of LXA4 signaling and modulation of stress responsive vitagene proteins could serve as a potential therapeutic target for AD-related inflammation and neurodegenerative damage.
Full-text available
Background The fruiting body of Hericium erinaceus has been demonstrated to possess anti-dementia activity in mouse model of Alzheimer’s disease and people with mild cognitive impairment. However, the therapeutic potential of Hericium erinaceus mycelia on Alzheimer’s disease remains unclear. In this study, the effects of erinacine A-enriched Hericium erinaceus mycelia (HE-My) on the pathological changes in APPswe/PS1dE9 transgenic mouse model of Alzheimer’s disease are studied. Results After a 30 day oral administration to 5 month-old female APPswe/PS1dE9 transgenic mice, we found that HE-My and its ethanol extracts (HE-Et) attenuated cerebral Aβ plaque burden. It’s worth noting that the attenuated portion of a plaque is the non-compact structure. The level of insulin-degrading enzyme was elevated by both HE-My and HE-Et in cerebral cortex. On the other hand, the number of plaque-activated microglia and astrocytes in cerebral cortex and hippocampus were diminished, the ratio of nerve growth factor (NGF) to NGF precursor (proNGF) was increased and hippocampal neurogenesis was promoted after these administrations. All the mentioned benefits of these administrations may therefore improve the declined activity of daily living skill in APPswe/PS1dE9 transgenic mice. Conclusions These results highlight the therapeutic potential of HE-My and HE-Et on Alzheimer’s disease. Therefore, the effective components of HE-My and HE-Et are worth to be developed to become a therapeutic drug for Alzheimer’s disease.
Full-text available
Background Hericium erinaceus (HE) is a well-known mushroom in traditional Chinese food and medicine. HE extracts from the fruiting body and mycelia not only exhibit immunomodulatory, antimutagenic and antitumor activity but also have neuroprotective properties. Here, we purified HE polysaccharides (HEPS), composed of two high molecular weight polysaccharides (1.7 × 105 Da and 1.1 × 105 Da), and evaluated their protective effects on amyloid beta (Aβ)-induced neurotoxicity in rat pheochromocytoma PC12 cells. Methods HEPS were prepared and purified using a 95 % ethanol extraction method. The components of HEPS were analyzed and the molecular weights of the polysaccharides were determined using high-pressure liquid chromatography (HPLC). The neuroprotective effects of the polysaccharides were evaluated through a 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay and an MTT assay and by quantifying reactive oxygen species (ROS) and mitochondrial membrane potentials (MMP) of Aβ-induced neurotoxicity in cells. Result Our results showed that 250 μg/ml HEPS was harmless and promoted cell viability with 1.2 μM Aβ treatment. We observed that the free radical scavenging rate exceeded 90 % when the concentration of HEPS was higher than 1 mg/mL in cells. The HEPS decreased the production of ROS from 80 to 58 % in a dose-dependent manner. Cell pretreatment with 250 μg/mL HEPS significantly reduced Aβ-induced high MMPs from 74 to 51 % and 94 to 62 % at 24 and 48 h, respectively. Finally, 250 μg/mL of HEPS prevented Aβ-induced cell shrinkage and nuclear degradation of PC12 cells. Conclusion Our results demonstrate that HEPS exhibit antioxidant and neuroprotective effects on Aβ-induced neurotoxicity in neurons.
Full-text available
The protective effects of extracellular and intracellular polysaccharides from Hericium erinaceus SG-02 on the CCl4-induced hepatic injury of mice were investigated in this work. By the analysis of GC, the extracellular polysaccharides (EPS) were composed of arabinose, mannose, galactose, and glucose with a ratio of 1:7:14:52, and the composition of intracellular polysaccharides (IPS) was rhamnose, xylose, mannose, galactose, and glucose with a ratio of 3:4:7:14:137. The model of hepatic injury of mice was induced by CCl4 and three tested levels (200, 400, and 800 mg/kg) of EPS and IPS were set as the experimental group. Results showed that the aspartate aminotransferase and glutamic pyruvic transaminase activities in serum were reduced by the supplement of EPS and IPS, while the blood lipid levels including cholesterol, triglyceride, and albumin were improved. In liver tissue, the lipid peroxidation and malondialdehyde were largely decreased, and the superoxide dismutase and catalase activities were significantly increased. The evidence demonstrated that the EPS and IPS of H. erinaceus SG-02 were protective for liver injury. The histopathological observations of mice liver slices indicated that EPS and IPS had obvious effects on liver protection.
Full-text available
Hericium erinaceus is an edible mushroom; its various pharmacological effects which have been investigated. This study aimed to demonstrate whether efficacy of oral administration of H. erinaceus mycelium (HEM) and its isolated diterpenoid derivative, erinacine A, can act as an anti-neuroinflammatory agent to bring about neuroprotection using an MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson’s disease, which results in motor disturbances, in addition to elucidating the mechanisms involved. Mice were treated with and without HEM or erinacine A, after MPTP injection for brain injuries by the degeneration of dopaminergic nigrostriatal neurons. The efficacy of oral administration of HEM improved MPTP-induced loss of tyrosine hydroxylase positive neurons and brain impairment in the substantia nigra pars compacta as measured by brain histological examination. Treatment with HEM reduced MPTP-induced dopaminergic cell loss, apoptotic cell death induced by oxidative stress, as well as the level of glutathione, nitrotyrosine and 4-hydroxy-2-nonenal (4-HNE). Furthermore, HEM reversed MPTP-associated motor deficits, as revealed by the analysis of rotarod assessment. Our results demonstrated that erinacine A decreases the impairment of MPP-induced neuronal cell cytotoxicity and apoptosis, which were accompanied by ER stress-sustained activation of the IRE1α/TRAF2, JNK1/2 and p38 MAPK pathways, the expression of C/EBP homologous protein (CHOP), IKB-β and NF-κB, as well as Fas and Bax. These physiological and brain histological changes provide HEM neuron-protective insights into the progression of Parkinson’s disease, and this protective effect seems to exist both in vivo and in vitro.
Full-text available
DOI 10.1007/s11557-015-1105-4. Online Medicinal mushrooms have become a compelling topic because the bioactive compounds they contain promise a plethora of therapeutic properties. Hericium erinaceus commonly known as “Houtou” or “Shishigashira” in China and “Yamabushitake” in Japan, has commonly been prescribed in Traditional Chinese Medicine (TCM), because its consumption has been shown to be beneficial to human health. The species is found throughout the northern hemisphere in Europe, Asia, and North America. Hericium erinaceus has been firmly established as an important medicinal mushroom and its numerous bioactive compounds have been developed into food supplements and alternative medicines. However, the correspondence of the active components that cause the observed effects is often not clear. The mushroom as well as the fermented mycelia have been reported to produce several classes of bioactive molecules, including polysaccharides, proteins, lectins, phenols, and terpenoids. Most interestingly, two classes of terpenoid compounds, hericenones and erinacines, from fruiting bodies and cultured mycelia, respectively, have been found to stimulate nerve growth factor (NGF) synthesis. In this review we examine the scientific literature to explore and highlight the scientific facts concerning medicinal properties of H. erinaceus. We provide up-to-date information on this mushroom, including its taxonomy and a summary of bioactive compounds that appear related to the therapeutic potential of H. erinaceus. See
2nd edition of the first book on the topic published in North America. The first edition was self-published in October, 1986. An exploration of tradition, healing, and culture. Covers the history of the uses of fungi for healing, including nutritional value, summary of cultural uses, history, and science on over 100 species. Shamanistic uses of hallucinogenic fungi. Botanica Press Imprint, published by The Book Publishing Co., Summertown, TN. 251 pp. with illustrations.
Hericium erinaceus (Bull.) Pers., also known as Yamabushitake, Houtou and Lion’s Mane, is capable of fortifying the spleen and nourishing the stomach, tranquilizing the mind, and fighting cancer. Over the past decade, it has been demonstrated that H. erinaceus polysaccharides possess various promising bioactivities, including antitumor and immunomodulation, anti-gastric ulcer, neuroprotection and neuroregeneration, anti-oxidation and hepatoprotection, anti-hyperlipidemia, anti-hyperglycemia, anti-fatigue and anti-aging. The purpose of the present review is to provide systematically reorganized information on extraction and purification, structure characteristics, biological activities, and industrial applications of H. erinaceus polysaccharides to support their therapeutic potentials and sanitarian functions.